Drugs / PBI-05204
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00554268 | Oct 2007 → Apr 2013 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02329717 | Apr 2015 → Dec 2016 | malignant pancreatic neoplasm | Phoenix Biotechnology, Inc | Unknown | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBI-05204 | “This trial evaluating a novel plant extract, PBI-05204, did not meet its primary endpoint of overall survival but did show signals of efficacy in heavily pretreated mPDA.” PMID 32452588 ↗ Jul 2020 |
| Action | Inhibit | “Oleandrin, the extract's major cytotoxic component, is a cardiac glycoside that has demonstrated antitumor activity in various tumor cell lines with a mechanism involving...” PMID 32452588 ↗ Jul 2020 |
| Route | Oral | “you will take the PBI-05204 capsules by mouth every day at the same time or twice a day (every 12 hours)” NCT00554268 ↗ |